Intralesional Agents in Dermatology: Pros and Cons

Jagdish Sakhiya, Dhruv Sakhiya¹, Jitesh Kaklotar, Bansu Hirapara, Madhav Purohit, Krishna Bhalala, Feral Daruwalla, Nimish Dudhatra

Sakhiya Skin Clinic, 2nd Floor, Ayush Doctor House, Station-Lal Darwaja Road, Surat, Gujarat, "B.J. Medical College, New Civil Hospital Asarwa, Ahmedabad, Gujarat, India

Abstract

Since introduced in 1961, intralesional (IL) agent has become an essential part of the dermatological practice. The term IL referred to the direct delivery of agent percutaneously into skin lesions. This therapeutic approach is relatively safe, easy to perform and applicable for a broad range of dermatological conditions. On the other hand, immediate side effects, including pain during administration, bleeding, high risk of infection and allergic reaction, and subsequent side effects involving skin changes such as atrophy, telangiectasia, pigmentary changes, and striae are usually associated with this modality. This review paper highlights the pros and cons of IL agents in modern dermatology practice.

Keywords: 5-Fluorouracil, bleomycin, botulinum toxin-A and hyaluronic acid fillers, corticosteroids, cryotherapy, immunotherapy, intralesional agents, mesotherapy, platelet-rich plasma

Key message: Because intralesional agents are relatively safe, easy to implement, and effective in a broad spectrum of dermatological indication with excellent success rate and minimum systemic side effects, the trends in its use have been emerging nowadays. Pros over the cons make it a preferred choice in the dermatology field.

Review

Intralesional (IL) agent therapy is the injection of a higher concentration of a agents directly into skin lesions without significant systemic absorption.¹ Historically, in 1961, it was first introduced by Hollander et al and, with the advent of time, has become a crucial part of dermatological therapy.² The main principle behind this method is the formation of an intradermal depot and sometimes subcutis depot which bypass the superficial barrier zone.¹ In this review paper, we have gathered evidence of associated pros and cons of various agents that are used via IL route. Patients having an active or herpetic infection at the injection site and the previous history of hypersensitivity are contraindicated for IL drug therapy. Supp I enlists the level of evidence (LoE) that is used in this review paper.

Pros Associated with Treatment of IL Agents

Faster action, extended duration of action due to depot/reservoir effect, reduction in the need for long-term topical therapy, less side effects of systemic treatment, improvement in patient compliance, and deeper penetrance than topical therapy are the major advantages of IL agent therapy. Furthermore, synergistic action can be obtained while combined with other treatment modalities, e.g., IL drugs with cryotherapy for keloids.

Most commonly used IL agents

Corticosteroids

Since the early 1950s, cortisone and hydrocortisone acetate suspensions have been widely accepted, before low-solubility formulations such as triamcinolone acetonide (2.5–10 mg/mL; 1 mg/cm²) have been developed, which is the most preferred agent to date.³ As per existing data reported by Verbov et al.³ revealed 0.1–0.2 mL/cm² dose per session with an interval of 3–6 weeks between two consecutive injections is most commonly used. The
maximum dosage of triamcinolone acetonide should not exceed 40 mg/mL/session. Table 1 illustrates the suggested strength of IL triamcinolone acetonide injections in various dermatological conditions. IL corticosteroid injection may be a beneficial therapeutic approach in cases where the topical formulation is not appropriate for use, mainly due to low potency and inefficient epidermal barrier penetration, or under clinical circumstances consistent with epidermal atrophy. This is a cost-effective, globally accessible and highly effective technique. This mode of therapy may be helpful to the dermatologist to avoid the notable and sometimes fatal side effects of systemic corticosteroid. When an additional local high dose of a corticosteroid is required to treat cutaneous disease, they can be used as a supplement to systemic therapy. In agreement with United States Food and Drug Administration (USFDA), IL triamcinolone (10 mg/mL) is on-label drug. As per stated, a 10 mg/mL dose is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), psoriatic plaques, necrobiosis lipoidica diabetorum and occasionally useful in cystic tumors of an aponeurosis or tendon.

### 5-Fluorouracil

Table 2 outlines the possible use of IL 5-fluorouracil (available as 50 mg/mL ampoule) in various dermatological condition. In each reported study, the interval between each session was 1 week. The upside of IL 5-fluorouracil is that it allows higher drug concentration in the lesion for a longer duration compared to topical formulation. It is used as “off label” drug for IL application.

### Botulinum toxin-A and hyaluronic acid fillers

In 2002, the USFDA-approved therapeutic botulinum toxin-A for various aesthetic uses. Evidence of beneficial effects of botulinum toxin-A in various aesthetic conditions are as follows: hypertrophic scars (2.5 U/cm²; LoE-Ib), keloid scars (100 U diluted with 5 mL of preservative-free saline; LoE-V), upper facial rejuvenation (10–40 IU with 4–6 months duration, for periorbital area 10–30 IU up to 3–4 months and forehead 6–15 IU used for 3–6 months; LoE-V), and multiple hidrocystomas (concentration of 7.5 U/0.1 mL; LoE-IV). This therapeutic approach is a simple and well tolerated. Compared to corticosteroid, IL botulinum toxin type A has minimal discomfort and other adverse events as well as no risk of scarring. USFDA-approved the three botox for cosmetic use: onabotulinum,

---

### Table 1: Suggested strength of IL triamcinolone acetonide injections from existing literature

| Author, year | Indications | Dosage/session (mg/mL) | Level of evidence |
|--------------|-------------|------------------------|------------------|
| Drugs.com, 2019 | Sarcoïdosis, localized psoriasis, hypertrophic lichen planus, nail lichen planus, and granuloma faciale | 5–10 | V |
| Marks et al., 2019, Riis et al., 2016, Drugs.com, 2019, Sar-Pomian et al., 2012 | Necrobiotic lipoïdica, hioderatitis suppurativa, lichen simplex chronicus, Pemphigus | 10 | V, IV, V |
| LeCourt et al., 2019 | Prurigo nodularis (more scarred pruriginous lesions may require higher concentrations) | 2.5 | V |
| Bolduc et al., 2018 | Alopecia areata | 2.5–10 | V |
| Tkachenko et al., 2018, Wang et al., 2014 | Discoid lupus erythematosus and vitiligo | 3 | V, V |
| Ahn et al., 2012 | Hemangiomas | 10–40 | IV |
| Coppola et al., 2018 | Keloids (thick or moderate/hypertrophic scars) | 40 or 10 | IIIa |
| Cyr et al., 2006 | Granuloma annulare | 2.5–5.0 | V |
| Leeming et al., 1965 | Cystic acne | 2–3 (not on face) 1–2 (face) | V |

### Table 2: Evidence of use of IL 5-fluorouracil along with dosage strength in the listed dermatological indication

| Author, year | Indications | Dose/total injections | Level of evidence |
|--------------|-------------|-----------------------|------------------|
| Mahajan et al., 2014 | Resistant localized plaque psoriasis | 0.1 mL/cm² 3 injection | Ib |
| Yazdanfar et al., 2008 | Warts | 4 mL of 50 mg/mL 5-fluorouracil and 1 mL of a mixture of 20 mg/mL [2%] lidocaine and 0.0125 mg/mL epinephrine/4–5 injections | Ib |
| Oh et al., 2005 | Infantile digital fibromatosis | 10 mg (0.2 mL)/5 injections | V |
| Morse et al., 2003, Kirby et al., 2010 | Squamous cell carcinoma, basal cell carcinoma and nonmelanoma skin cancer | 0.8 to 2.4 mL/8 injections | V, IIa |
| Gupta et al., 2002, Fitzpatrick, 1999 | Keloids | 50–150 mg/16 injections | Ia |
| | | 0.9 mL of 5-FU+0.1 mL triamcinolone acetonide (10 mg/mL)/average 5–9 injections | V |
abotulinum, and incobotulinum. Mentioned all are based on botulinum toxin A.

**Platelet-rich plasma**

Treatment details of platelet-rich plasma (PRP) in various dermatological conditions are enlisted in Table 3.[29-36] PRP was prepared using a double centrifugation technique. PRP is a safe, simple, inexpensive, and biocompatible procedure. Its ability to facilitate wound healing and no probabilities of allergic reactions have attracted attention in diverse medical fields. Both the PRP treatment and the device used to prepare it are “cleared” by the FDA, rather than “approved” as PRP is not a drug and in FDA, D stands for Drug.

**Mesotherapy**

It is an “intra-dermotherapy” rather than an “IL therapy.” In IL therapy, the injection is targeted inside the skin condition to be treated regardless of whether the skin lesion is in dermis or subcutis, whereas, in mesotherapy, the depth of needle penetration exceed more than 4 mm into the skin and injections are regularly spaced.[37] As per the literature review, mesotherapy has shown promising outcomes in the treatment of androgenic alopecia (LoE-IIb),[38] telogen effluvium (LoE-V), and localized fat dissolution (phosphatidylcholine, LoE-V), and localized fat dissolution (phosphatidylcholine, LoE-V), and localized fat dissolution (phosphatidylcholine, etc.) (LoE-V) and acute cutaneous leishmaniasis (LoE-IIb).[39] It is a nonsurgical, minimally invasive method having a rapid rate of onset, due to the short time necessary to reach the site of action, as well as a prolonged local action. It is not FDA approved.

**Cryotherapy**

It is an “off label” therapy. IL cryotherapy with liquid nitrogen has been used, along with steroids, for the treatment of keloids and hypertrophic scars (LoE-IV).[40] IL cryotherapy allows for focused destruction of keloid scar tissue with minimal surface damage to the epidermis. Also, it claims to enhance volume reduction and decrease recurrences while minimizing the risk of hypopigmentation.

**Bleomycin**

Bleomycin is not USFDA-approved drug for IL therapy despite it is used in the treatment of the various conditions. It is marketed as bleomycin sulfate powder lyophilized 15 U/vial (reconstituted with 1–5 mL sterile water for injection or 0.9% normal saline) or 30 U/vial (2–10 mL water/normal saline). It penetrates poorly through cell membranes. Interestingly, penetration can be enhanced by disrupting cell membranes when reconstituting with local anesthetic (lignocaine).[41]

As shown in Table 4, with varying dose, it is beneficial in the field of dermatology.[42-58] IL bleomycin offers the advantage of low dose than the usual systemic dose (30 mg twice weekly), no significant systemic adverse effects and high patient satisfaction. It does not require special puncture needles or technical expertise and there is a minimal drug wastage from spills. Compared to cryotherapy, it was also proved to be efficient in the treatment of plantar warts in terms of cure rate, less number of session, and low recurrence rate.[54]

**Immunotherapy**

This therapeutic modality utilizes the ability of the immune system to mount a delayed-type hypersensitivity response to various antigens and also the wart or tumor tissue. In today’s practice, measles, mumps, and rubella vaccine (MMR) (0.1 mL/lesion, 1–3 weekly, up to 3–6 weeks/till complete resolution) (LoE-IIb),[53] mycobacterium indicus pranii (LoE-IV) [(0.1 mL/lesion weekly till 10 weeks or complete resolution)],[59] bacillus Calmette–guérin (BCG) vaccine (0.1 mL/lesion every 2 weeks, till 5 doses or complete resolution of warts) (LoE-V),[60] candida antigen (0.1–0.3 mL (1:1000), repeated after 3 weeks until complete resolution/4 weeks) (LoE-IV),[58] purified protein derivative (PPD) or tubercul test antigen (0.1/mL/lesion injected 1–3 weekly till complete resolution/12 weeks) (LoE-IIb)[69] are the most commonly used IL immunomodulator agents. Apart from this, other antigens such as trichophyton skin test antigen have also shown satisfactory results with varied success in the therapy of warts. Notably, no scarring or pigmentation has been observed unlike other destructive warts therapies, and lower recurrence rate is further benefits. At present, cryosurgery, laser surgery, electrosurgery, bleomycin, curettage, and topical keratolytic applications are available alternatives for the treatment of warts. These modalities are associated with pain, unsightly, and recurrences. In new research era, talimogene laherparepvec, a herpes-based oncolytic viral injectable therapy, is the first USFDA-approved IL therapy for advanced melanoma. Apart from this, other IL therapies including PV-10 (Rose Bengal), IL-12

---

**Table 3: The recommended dose of PRP in various dermatological conditions**

| Author, year | Indication                          | Treatment                        | Level of evidence |
|--------------|------------------------------------|----------------------------------|-------------------|
| Gopinath et al., 2019[59] | Chronic nonhealing cutaneous ulcers | 6 injections/1 week interval     | IV                |
| Tuknayat et al., 2018[59]  | Melasma                            | 3 injections/1 month interval    | C                 |
| Mahajan et al., 2018[59]   | Chronic localized vitiligo         | 6 injections/2-week intervals    | C                 |
| Gamil et al., 2017[59]     | Striae distensae                   | 3 injections/1 month interval    | Ib                |
| Goyal et al., 2017[59]     | Male pattern baldness              | 6 injections (0.1 mL per cm³)/ 21 days interval | Ib                |
| Behnia-Willison et al., 2016[59] | Lichen sclerosus          | 3 injections/4 to 6 weeks apart and again at 12 months | IV                |
| Shumoez et al., 2015[59]   | Alopecia areata                    | 3 injections/3-week interval     | IIIb              |
| Jeong et al., 2011[59]     | Refractory lipodermatosclerosis   | 5 injections/2-week interval     | V                 |
plasmid electroporation, and Coxsackievirus A21 have shown favorable clinical outcomes.[60]

**RARELY Used IL Drug Therapy**

**Tranexamic acid**

It is off-label treatment for melasma. Published report by Veggalam and Perumalla (LoE-IIb) and Pazyar et al. (LoE-IIb) suggested its potential role in the treatment of melasma (0.05 mL of 4 mg/mL—1 cm apart, once a week ×12 weeks).[61,62] The use of oral and intravenous dosage forms is limited due to its adverse effects and contraindications resulted by its thrombolytic property. Its IL administration was reported to be an effective way of treatment for melasma with minimum risk of adverse effects.

| Table 4: With varying dose, the beneficial effect of bleomycin in the field of dermatology |
| --- |
| **Author, year** | **Indication** | **Dose** | **Level of evidence** |
| Dinh Huu Nghi et al., 2019[42] | Keloids | 0.2–0.4 mL/cm² (maximum volume per session 3.5 mL, the interval between each session: 4 weeks and the total number of session depend on the cosmetic outcome) | IV |
| Unni et al., 2017[43] | Common warts | Concentration: 1 unit/1 mL. Maximum 2 injection was given | Ib |
| Aziz-Jalali et al., 2014[44] | Resistant warts | 1 mg/mL IL/1–3 doses/every 4 weeks | IV |
| Kumar et al., 2012[45] | Lymphangioma | 0.5 mg/kg body weight, not exceeding 10 units at a time | IIa |
| Soni et al., 2011[46] | Palmo-plantar and periungual warts | 0.1–2 mL/session, monthly, up to 4 injections/wart | Ib |
| Dhar et al., 2009[47] | Cutaneous warts | Concentration: 1 mg/1 mL (0.1% or 1 unit/mL). Less than 2 mL of 0.1% bleomycin solution was given in a single visit. | Ib |
| Gyurova et al., 2006[48] | Multiple basal cell carcinomas | 3 IU bleomycin solution every 48 h (bleomycin was dissolved in normal saline solution to a concentration of 2 IU/mL and further diluted with an equal amount 1% lidocaine hydrochloride); approximately 0.375 mL of the solution was injected into each lesion. In total, seven injections were given. | V |
| Pienaar et al., 2006[49] | Hemangiomas and vascular malformation | 0.3–1 mg/kg, up to a maximum of 15 mg/month | IIb |
| Heller et al., 1998[50] | Cutaneous and subcutaneous tumors | The dose of IL bleomycin (electrochemotherapy) was based on tumor volume. It was administered at a concentration of 5 Units/mL. The dosage was as follows: 0.5 Units for tumors up to 100 mm³, 0.75 Units for tumors 100–150 mm³, 1.0 units for tumors 150–500 mm³, 1.5 units for tumors 500–1000 mm³, 2.0 units for tumors 1000–2000 mm³, 2.5 units for tumors 2000–3000 mm³, 3.0 units for tumors 3000–4000 mm³, 3.5 Units for tumors 4000–5000 mm³, and 4 Units for tumors larger than 5000 mm³. | IIb |
| Soyuer, 1988[51] | Leishmaniasis cutis | 1% Solution of bleomycin sulfate in normal saline solution/1.5 mg of bleomycin/one injection | V |
| Sayama et al., 1983[52] | Keratoacanthoma | 0.2 to 0.4 mg according to the size of the lesions | IV |
| Figueroa et al., 1980[53] | Condyloma acuminatum | 1 mg of bleomycin diluted in 1 cc of sterile water injected. 0.5 and 5 mg per session/ at intervals of 2 to 3 weeks/total injection range 1–4 | IV |

| Table 5: Describes the indications of IL interferons in dermatology |
| --- |
| **Author, year** | **Indication** | **Interferon** | **Dose/duration** | **Level of evidence** |
| Mahajan et al., 2020[54] | Leishmaniasis | IFN-γ | 1–30 μg/m² | V |
| Cornell et al., 1990[55] | Basal cell carcinoma | IFNα-2b | 1.5 million IU on 3 alternate days per week for 3 consecutive weeks* | Ib |
| Tourani et al., 1989[56] | Cutaneous B-cell lymphoma | IFNα-2a | 3 to 9 million/units/session and the sessions were repeated three times a week for several months | V |
| Kütting et al., 1997[57] | | | | |
| Wollina et al., 1998[58] | and Wollina et al., 1999[59] | Cozzio et al., 2006[60] | | |
| Oh et al., 2004[61] | Keratoacanthoma | IFNα-2b | 3MIU per week for 4–6 week | |
| Lacy et al., 2002[62] | Peyronie's disease | IFNα-2b | 1–2 MIU weekly for 3–5 weeks | |
| Welander et al., 1990[63] | Genital warts | IFNα-2b | 1 MIU three times a week on alternative day for a total of nine injections | Ib |
| Wolff et al., 1985[64] | Mycosis fungoides | IFNα-2 | 2 × 10⁸ units three times weekly for 4 weeks in one lesion | Ib |

*IFN = interferon; MIU = Million International Unit

*For larger tumor size, more doses have been given.


Interferons
Interferons (IFNs) are glycoproteins belonging to the family of cytokines with antiviral, antitumor, and immunomodulatory activities. Table 5 describes the indications of IL interferons in dermatology.[63–73] IL interferon may be worked as a beneficiary in some situations such as patients for whom surgery would not suitable due to the presence of hemostasis, increased risk of infection or an inability to tolerate the rigors of surgery or some cases in which malignancy occurring in particular locations (anatomic regions tricky to operate on or where scarring might result in functional impairment). Only IFN-α-2b is “on-label” for hairy cell leukaemia, malignant melanoma, follicular lymphoma, follicular non-Hodgkin’s lymphoma, AIDS-related Kaposi’s sarcoma chronic, and hepatitis C.[74]

Sclerosants
These are “off-label” used agents. Various studies reported a favorable outcome of sodium tetradecyl sulfate in the mentioned indication: intraoral hemangiomas (LoE-V),[74] late-onset eczema angiomaticus hamartoma (IL sclerosant-polidocanol with 2 mL of 3% ethoxysclerol, total five sessions; the 2-week interval between each session; LoE-V),[74] vascular malformation (30 mg/mL of sodium tetradecyl sulfate; LoE-V),[74] pyogenic granuloma and mucoule [0.5–1 mL of 3% polidocanol (Asklerol); LoEIV],[74] cystic hygromas (0.5 mg/kg, at intervals of 2 weeks; LoE-V),[74] wrist ganglion cysts (sodium tetradecyl sulphate; 1–2 cc of inj.; LoE IV),[80] and pseudocyst (3% sodium tetradecyl sulfate; LoE-V).[80]

This mode of treatment with a variety of sclerotic also has shown beneficial effects in telangiectasias, venuletiasias of lower extremities, lymphangioma, and circumscriptum in a dose of 0.1 to 0.5 mL/site at weekly intervals (LoE-V).[1] IL sclerotherapy is a noninvasive, economic technique, and there is a low risk of hemorrhaging. The reported advantages of sodium tetradecyl sulphate as a sclerosing agent are the absence of pain, no hemolysis, less hyperpigmentation, complete regression of low vascular lesions and very low incidence of allergic reactions.

Amphotericin B
It is not USFDA approved. Mushtaq et al.[82] and Nikandish et al.[83] have been promisingly attempted in lesions of cutaneous leishmaniasis (case series: the dose of 2.5 mg/mL/week, the total number of dose 3 to 10 depending severity of disease) (LoE-IV) and ocular leishmaniasis (1.5 mg per injection/week till 6 weeks) (LoE-V), respectively. Since 1950, antimoniate compounds has recognized as first-line treatment for cutaneous leishmaniasis. At the current time, growing antimonal tolerance and increasing prevalence of the disease worldwide; leads to the development of other better alternatives. With advance research, IL amphotericin comes out an as good option for this condition. IL amphotericin B is a feasible and less expensive alternative to antimoniate and especially, useful in patients who were resistant or allergic to meglumine antimoniate. The mechanism of leishmanicidal action is believed to be drug-binding to parasite ergosterol precursors, such as lanosterol, causing disruption of the parasite membrane.

Methotrexate
However, it is a off-label drug. Studies have reported the potential role of methotrexate in keratoacanthomas (0.4 to 1.5 mL of 12.5 or 25 mg/mL/total 1–2 injections) (LoE-IV).[84] Methotrexate is less than 200 INR. Each vial can be used multiple times.

Vincristine and vinblastine
Vincristine, not USFDA approved for IL application, a universally known vinca alkaloid antibiotic drug that disrupts microtubular function which is used in haematological neoplasms and nephroblastomas. Thus, its usage in epithelial neoplasms is a mainstay for the activity in Kaposi sarcoma (0.03–0.08 mg/mL of vincristine sulphate at a concentration of 1 µg/mL) (LoE-IIIb).[89] Besides, another vinca alkaloid agent, such as vinblastine, is also recommended for systemic therapy because of its reduced neurotoxicity.[89] Vinblastine is marked in 10 mL vials and used in a dosage of 1 mg/mL. Approximately 0.03–0.1 mL of the drug is injected, after diluting with 0.9% normal saline (LoE-IV). IL vincristine gives excellent therapeutic response in Kaposi sarcoma with full healing and recovery of function, low cutaneous reactions, and no systemic toxicity.

Verapamil
It is “off-label” drug. Levine et al.[90] have demonstrated the beneficial effect of IL injection of calcium antagonist verapamil in the therapy of Peyronie’s disease (5 mg/2 cc diluted to 10 cc total volume with injectable saline) (LoE-IV). According to Margaret Shanthi et al.,[91] IL verapamil combined with triamcinolone is preferred choice in the treatment of keloids and hypertrophic scars when given in a dose of 2.5 mg/mL every 3 weeks for 6 months (LoE-Ib). This outcome was supported by the verdicts of Ahuja et al.[92] concluded previously mentioned combination is nearly similarly efficient with very few adverse effects.
and provides a remedial alternative for treating larger and recalcitrant scars (LoE-Ib). Clinically, this drug is safe for patients with Peyronie’s disease if precautions are taken to prevent injury to the dorsal neurovascular bundle. Compared to other modes of therapy, it appears to induce a rapid, beneficial effect in some patients (those with angulation of less than 30°) for reduction of plaque size. Patients with localized plaque are the most qualified for IL injection of verapamil. IL verapamil may be a proper choice compared to triamcinolone in the treatment of hypertrophic scars and keloids, as patient acceptability is good for IL verapamil and lower adverse drug reactions reported with its use.

**Photodynamic therapy**

IL photodynamic therapy is off-label and its uses continue to increase. IL photodynamic therapy is a modality in which photosensitizers such as aminolevulinic acid have been inserted intralesionally and then photosensitizers are exposed to a specific wavelength of light, creating a form of oxygen that destroys surrounding cells. Various published literature documented the use of IL photodynamic therapy with a considerable improvement in hidradenitis suppurativa [Photosensitizer: 5% 5-aminolevulinic acid (ALA); radiation: multimodiode (630nm) 1.2 watts (W), fluence 180 Joules (J/cm²); Follow-up 5–7 week interval] (LoE-IV), [93] myxoid cysts [Photosensitizer: 5% 5-ALA; radiation: multimodiode (630nm) 1 Watts (W), fluence 240 Joules (J/cm²); Follow-up 2 months] (LoE-IV), [94] pyogenic granuloma [Photosensitizer: Nearly 0.3 mL/cm² of 5-ALA, 20% solution; radiation: Waldmann photodynamic therapy 1,200 L (600–720 nm), light dose of 100 J/cm², 1 W, fluence 100 mW/cm²; follow-up after 2 week] (LoE-IV), [95] cutaneous malignancies (nodular basal cell carcinoma, squamous cell carcinoma) [Photosensitizer: nearly 0.3 mL/cm³ of 5% 5-ALA under 2% mepivacaine hydrochloride anesthesia; radiation: a red light at 100 J/cm² (LoE-IV) and acne [Photosensitizer: 0.1–0.15 cm³ of 5-ALA; radiation: long-pulsed dye laser, passes 2-3, 7.5 J/cm² fluence, 10ms pulse duration, 10mm spot size, a dynamic cooling spray of 30ms with a 30ms delay, interval between each session 1 month, total session 3] (LoE-IV). [96] In comparison with systemic photosensitizer administration, there are minimum skin phototoxicity and maximum local tissue destruction. It is prophesied that the preceding will result in less circumferential damage predisposing the formation of strictures. The upside of IL photodynamic therapy includes as following mentioned features:

- Safe, minimally invasive, and effective treatment
- Selective destruction of the tumors
- No pain
- Does not alter adjacent tissue and organs
- Proven clinical effectiveness
- Effectiveness in dermal tumors with great depth and thickness, impossible to obtain with other noninvasive techniques
- Fast, comfortable procedures with nor downtime neither side effects
- Accurate control of energy
- No hospital stay

**Rituximab**

It is off-label used drug. This anti-CD20 monoclonal antibody was attempted favorably in oral pemphigus vulgaris (5 mg/cm²; total two injections on days 1 and 15) (LoE-IV) [98] and primary cutaneous B-cell lymphomas (10 mg/mL [3 mL], total nine injections, 3 times/week followed by a 3-week treatment-free period) (LoE-IV). [99] IL administration allows local delivery of the drug, lacks the adverse effects of intravenous administration, reduces the amount of drug administered (<10% of the intravenous dose), and therefore is less expensive. Being an outpatient procedure also offers an advantage. No reported cutaneous atrophy and scars.

**Cyclosporine**

Many authors describe their experience in managing psoriasis with great success by using IL cyclosporine at a dose of 17 mg/mL/3 times weekly/up to 4 weeks. LoE-IV however, it is not FDA approved drug. [100,101]

**Mistletoe extract**

Traditionally, it is a whole remedy originating from *Viscum album* L., used in treatment of primary cutaneous B-cell lymphoma at a dose of 20 mL/month [20 mg/mL/ampoule] (LoE-V). [102] It is not FDA approved for the treatment of cancer.

**Placental extract**

The placental extract comprises of growth factors, anti-inflammatory agents, and antiplatelet activation and used as off-label agents. It is mainly reported as adjuvant therapy with IL injections dexamethasone has shown promising result in the mouth opening in patients with oral submucous fibrosis (LoE-IIIb). [103]

**Vitamin D3**

It is not approved by USFDA for IL application. Existing data postulated the efficacy and safety of IL vitamin D3 in recalcitrant warts (0.2 to 0.5 mL, 600,000 IU, 15 mg/mL; a maximum of 5 warts were injected per session at 3-week intervals until resolution or for a maximum of four treatments) (LoE-IV) [104] multiple cutaneous warts [0.2 mL, 15 mg/mL; the interval between each session is 2 week, maximum of four sessions or until complete clearance] (LoE-IV) [105] common warts (0.2 mL, 300,000 IU, multiple sessions up to complete clearance or maximum four sessions) (LoE-IIIb) [106] and plantar warts (0.3 mL, 100,000 IU, 2.5 mg/mL) (LoE-IIIa). [107] IL vitamin D3 is an inexpensive, safe modality to treat multiple warts in developing countries.
Sodium thiosulfate

IL sodium thiosulfate in the concentration of 250mg/mL may effectively treat patients with a localized cutaneous disease like calciphylaxis (LoE-V)\(^{[108]}\) and calcinosis cutis (LoE-V).\(^{[109]}\) This is off-label, usually well-tolerated, and inexpensive treatment. Direct targeted action with minimal systemic side effects is the main advantages of this therapy over systemic treatment. The time required for progressive healing of the wound is usually less. It may be used in both nonuremic and uremic calciphylaxis, and it is of special interest in bedridden elderly patients. Furthermore, it does not require any hospitalization and can be done in the outpatient clinic setting. The procedure is easy to learn, and any physician or resident can perform it after learning the injection techniques properly.

2% Zinc sulfate

This therapeutic approach has been shown encouraging result in plane warts (LoE-V),\(^{[110]}\) common warts (LoE-IIb),\(^{[111]}\) cutaneous leishmaniasis (LoE-IIIb),\(^{[112]}\) and basal cell carcinoma (LoE-V).\(^{[48]}\) It is used as an off-label drug.

Pentavalent antimony compound

It is not USFDA approved. Meglumine antimoniate (20mg/kg/day) and sodium stibogluconate (SSG) are the main compounds belong to this category. Effectiveness of pentavalent IL antimoniate infiltration therapy for cutaneous leishmaniasis was studied and promising results have been obtained from gathered evidence (LoE-Ia).\(^{[113]}\) With this therapy, we can achieve lower total doses of antimony (and thus less toxic effects) and a more flexible schedule without the requirement of daily drug administration. Also, this modality does not require investment in equipment, which makes it feasible to implement in the short term.

Cons Associated with Various IL Drug Therapy

Like other medication therapy, IL drug treatment also has some drawbacks, which have made it a matter of debate. Corticosteroids tend to disrupt collagen and elastic fibers and cannot be utilized in the circumstances, in which destruction is contraindicated like acne, necrobiosis lipoidica, and discoid lupus erythematosus. The risk of infection is higher, but there is no risk of hepatitis virus or HIV transmission. In some cases, a significant accidental damage to the eyes has been reported. The Dermo-Jet is not appropriate for injection to the proximal nail fold, as permanent dystrophy of the nail has been reported.\(^{[114]}\) With the use of IL 5-fluorouracil, fewer instances of recurrences were elicited.\(^{[115]}\) Usually, botulinum toxin type A was more expensive and was more difficult to procure. PRP is also more expensive and the process to obtain the PRP requires more time for the patient and the physician. In IL mesotherapy, cryotherapy and vitamin D3 multiple sittings are required. Principal disadvantages of the IL interferon-α-2b are high cost, multiple visits and prolonged follow-up. Hence, interferon could be now prescribed only for cases in which the cosmetic outcome is of predominant concern. Pulmonary fibrosis is associated with a high dosage of bleomycin.\(^{[116]}\) Also multiple treatment sessions are required with this modality. Apart from reported side effects, there is no significant disadvantage associated with IL scleransants therapy. The downfall with IL immunotherapy is pain associated with the injection, so children who prefer the nonpainful topical application and for patients with warts in extremely painful sites, it is futile.\(^{[58]}\) Immunotherapy using diphenylcyclopropenone and squaric acid dibutyl ester is limited by allergic contact dermatitis, urticarial reactions, and pigmentary disturbances. Autologous vaccine therapy is limited by the oncogenic potential of the virus. The risk of cutaneous TB is associated with intralesional BCG vaccine. IL methotrexate contraindicated under various conditions includes pregnancy or breastfeeding, and individuals with an active infection, blood dyscrasias, drug interactions, hepatic disease, or renal disease. In IL methotrexate, treated patients with renal insufficiency, the rare incidence of pancytopenia has been documented.\(^{[117]}\) Hence, a baseline and follow-up laboratory monitoring is recommended for patients treated with IL methotrexate.\(^{[118]}\) There is a major drawback associated with the use of IL vinca alkaloids: it requires the physician to perform the injection. IL photodynamic therapy is contraindicated in various conditions includes a nonresponsive tumor, a history of porphyria, systemic lupus erythematosus, photosensitive dermatoses, and allergy to the active ingredients in the photosensitizer, which is considerably rare. The main drawback of IL rituximab in secondary cutaneous B-cell lymphomas is the risk of relapse by not treating the systemic disease.\(^{[119]}\) The main drawback of IL sodium thiosulfate was the pain during injections. To address this issue, before injecting sodium thiosulfate, local anesthesia with lidocaine 1% was given. This procedure probably is enhanced tolerability of formulation. On rare occasion, Hoigne phenomenon is associated with the use of more than 200 pharmacological agents including meglumine antimonite, and mainly occurs due to infusion of the drug. This reaction having psychiatric symptoms, disturbances of perceptions and intense anxiety as main clinical features. Furthermore, neurological signs and symptoms including panic, fear of death, alteration of consciousness, hallucinations, accompanied by tachycardia, tachypnea, hypertension, and numbness in the extremities may also be observed. In this situation, the withdrawal of the offending drug is a good way to rapidly attenuate clinical symptoms. Specific side effect for individual drugs belongs to this category is summarized in Supp II.

Conclusion

To sum up, IL therapy is a simple, safe office procedure when used carefully and judiciously. It is integral part for doing good dermatologic practice in modern time.
Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Savant S, editor. Intralesional therapy. In: Textbook of Dermatologic and Cosmetology. 2nd ed. Mumbai, India: ASCAD; 2005. pp. 100-6.
2. Hollander A. Intralesional injections of triamcinolone acetonide; a therapy for dermatoses. Antibiot Med Clin Ther (New York) 1961:8:78-83.
3. Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol 1976;94(suppl 12):51-8.
4. Triamcinolone Dosage. Medically reviewed by Drugs.com. Available at: https://www.drugs.com/dosage/triamcinolone.html. [Last accessed 2000 Jan 3].
5. Marks JG, Jeffrey J, Miller MD. Dermal induration. In: Lookingbill and Marks’ Principles of Dermatology. 6th ed. [London]: Saunders Elsevier; 2019.
6. Riis PT, Boer J, Prens EP, Saunte DM, Deckers IE, Emtestam L, et al. Efficacy of perilesional and intralesional triamcinolone acetonide injections in pemphigus vulgaris lesions of the scalp: An effective therapeutic option. Clin Exp Dermatol 2018;43:168-70.
7. LeCourt AP, Dela Rosa KM. Prurigo nodularis treatment and management. MedScape. Available at: https://emedicine.medscape.com/article/1088032-treatment#d10; 2019. [Last accessed 2000 Jan 3].
8. Bolduc C, Lui H, Shapiro J. What is the role of triamcinolone acetonide (Kenalog) in the treatment of alopecia areata? MedScape. Available at: https://www.medscape.com/answers/1069931-62726/what-is-the-role-of-triamcinolone-acetonide-kenalog-in-the-treatment-of-alopecia-areata. [Last accessed 2000 Jan 3].
9. Tkachenko E, Vleugel RA, Callen JP. What is the role of corticosteroid therapy in the treatment of discoid lupus erythematosus (DLE)? MedScape. Available at: https://www.medscape.com/answers/1065529-119036/what-is-the-role-of-corticosteroid-therapy-in-the-treatment-of-discoid-lupus-erythematosus-dle. [Last accessed 2020 Jan 3].
10. Wang E, Koo J, Levy E. Intralesional corticosteroid injections for vitiligo: A new therapeutic option. J Am Acad Dermatol 2014;71:391-3.
11. Ahm AH, Hashim Ahmed A, Abbas Alhamami F. Intralesional triamcinolone injection in the management of cutaneous hemangiomas in children. Med J Babylon 2012;9:1.
12. Coppola MM, Segreto SR, Persichetti FP. Triamcinolone acetonide intralesional injection for the treatment of keloid scars: Patient selection and perspectives. Clin Cosmetic Invest Dermatol 2018;11:387-96.
13. Cyr PR. Diagnosis and management of granuloma annulare. Am Fam Physician 2006;74:1729-34.
14. Leeming JA. Intralesional triamcinolone in the treatment of cystic acne. S Afr Med J 1965;39:567-71.
15. Firooz A, Tehranchia-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol 1995;20:363-70.
16. Wakhne Y. FDA safety changes: Kenalog-10 and Kenalog-40, Depacon, Depakene. MedScape. Available at: https://www.medscape.org/viewarticle/551786. [Last accessed 2020 Mar 12].
17. Mahajan BR, Singla M. Evaluation of intralesional 5% 5-fluorouracil in resistant localized plaque psoriasis. Indian Dermatol Online J 2014;5:287-90.
18. Yazdanfar A, Farshchian M, Fereydoonnejad M, Farshchian M. Treatment of common warts with an intralesional mixture of 5-fluorouracil, lidocaine, and epinephrine: A prospective placebo-controlled, double-blind randomized trial. Dermatol Surg 2008;34:656-9.
19. Oh CK, Son HS, Kwon YW, Jang HS, Kwon KS. Intralesional fluorouracil injection in infantile digital fibromatosis. Arch Dermatol 2005;141:549-50.
20. Morse LG, Kendrick C, Hooper D, Ward H, Parry E. Treatment of squamous cell carcinoma with intralesional 5-fluorouracil. Dermatol Surg 2003;29:1150-3; discussion 1153.
21. Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: A practical review. J Am Acad Dermatol 2010;63:689-702.
22. Gupta S, Kalra E. Efficacy and safety of intralesional 5-fluorouracil in the treatment of keloids. Dermatology 2002;204:130-2.
23. Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 1999;25:224-32.
24. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional butulinum toxin type A injections: A preliminary report. Aesthet Plast Surg 2009;33:409-12.
25. Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. Am J Phys Med Rehabil 2010;89:153-5.
26. Nanda S, Bansal S. Upper face rejuvenation using botulinum toxin and hyaluronic acid fillers. Indian J Dermatol Venereol Leprol 2013;79:32-4.
27. Gheisari M, Hamedani B, Robati R, Mozafari N. Intralesional butulinum toxin-A injection for the treatment of multiple eccrine hidrocystomas. J Cosmet Laser Ther 2018;20:287-92.
28. Gopinath VPK, Simi VM, Basheer Ahammed K, Farisa PM, Ali Rishad CM. Intralesional autologous platelet rich plasma therapy in chronic nonhealing cutaneous ulcers: An interventional study from a tertiary care centre in North Kerala. Int J Res Dermatol 2019;5:116-22.
29. Tukayat A. Clinical efficacy of intralesional platelet rich plasma in melasma. J Clin Exp Dermatol Res 2018;9:27.
30. Mahajan R, Ninama K, Shah H, Bilimoria F. Effect of intralesional platelet rich plasma in chronic localized vitiligo. Int J Res Dermatol 2018;4:550-5.
31. Gamal HD, Ibrahim SA, Ebrahim HM, Albalat W. Platelet-rich plasma versus tretinoin in treatment of striae distensae. Dermatol Surg 2018;44:697-704.
32. Goyal V, Mathur D, Nijhawan M. A randomized controlled study of the effect of intralesional injection of autologous platelet rich plasma (PRP) compared with topical application of 10% minoxidil in male pattern baldness. Indian J Clin Dermatol 2017;1:33-4.
33. Behnia-Willison F, Pour NR, Mohamadi B, Willison N, Rock M, Holten IW, et al. Use of platelet-rich plasma for vulvovaginal autoimmune conditions like lichen sclerosus. Plast Reconstr Surg Glob Open 2016;4:e124.
34. Shammez H, Prasad PVS, Kaviarasan PK, Deepika R. Intralesional platelet rich plasma vs intralesional triamcinolone in the treatment of alopecia areata: A comparative study. Int J Med Res Health Sci 2015;4:118-22.
35. Jeong KH, Shin MK, Kim NI. Refractory lipodermatosclerosis treated with intralesional platelet-rich plasma. J Am Acad Dermatol 2011;65:157-8.
36. Konda D, Thappa DM. Mesotherapy: What is new? Indian J Dermatol Venereol Leprol 2013;79:127-34.
37. Gajjar PC, Mehta HH, Barvaliya M, Sonagara B, Dave S. Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: Comparison of conventional technique with mesotherapy gun. Int J Trichol 2019;11:58-67.
38. Kashani MN, Sadr B, Nilforoushzhadeh MA, Arasteh M, Babakoohi S, Firooz A. Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: Comparison of conventional technique with mesotherapy gun. Int J Dermatol 2010;49:1034-7.
39. Oh Boyle CP, Shayaan-Arani H, Hamada MW. Intralesional cryotherapy for hypertrophic scars and keloids: A review. Scars Burn Heal 2017;3:2059513117702162.
40. Smith DD. Bleomycin and the skin. DermNet MZ. Available at: https://dermnetnz.org/topics/bleomycin/. [Last accessed 2020 Mar 6].
42. Dinh Huu N, Nguyen Huu S, Le Thi X, Nguyen Van T, Thi Minh PP, Trinh Minh T, et al. Successful treatment of intralesional bleomycin in keloids of vietnamese population. Open Access Maced J Med Sci 2019;7:299-6.

43. Unni M, Tapare V. Intralesional bleomycin in the treatment of common warts. Indian J Drugs Dermatol 2017;3:73-6.

44. Aziz-Jalali M, Ghafarpour G, Rezaei MR, Heshmatzadeh Behzadi A, Rohani Nasab M, Nilloroshazadeh M. Efficacy of intralesional bleomycin in the treatment of resistant warts. J Skin Stem Cell 2014;1:e18875.

45. Kumar V, Kumar P, Pandey A, Gupta DK, Shukla RC, Sharma SP, et al. Intralesional bleomycin in lymphangioma: An effective and safe non-operative modality of treatment. J Cutan Aesthet Surg 2012;5:133-6.

46. Soni P, Khandelwal K, Aara N, Mehta RD, Bumb RA. Efficacy of intralesional bleomycin in palmar-plantar and periungual warts. J Cutan Aesthet Surg 2011;4:188-91.

47. Dhar SB, Rashid MM, Islam A, Bhuiyan M. Intralesional bleomycin in the treatment of cutaneous warts: A randomized clinical trial comparing it with cryotherapy. Indian J Dermatol Venereol Leprol 2009;75:262-7.

48. Gyurova MS, Stancheva ZN, Arnaudova MN, Yankova R. Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas. Dermatol Online J 2006;12:25.

49. Pienaar S, Tagami H. Treatment of keratoacanthoma with electrochemotherapy using intradermal bleomycin. Cancer 1998;83:148-57.

50. Soyuer B, Levent Y, Cargi R, Yilmaz M, Atasoy S. Intralesional bleomycin therapy for Leishmaniasis cutis. Arch Dermatol 1988;124:1571.

51. Sayama S, Tagami H. Treatment of keratoacanthoma with bleomycin. Br J Dermatol 1983;109:449-52.

52. Figueroa S, Gennaro AR. Intralesional bleomycin injection in the treatment of condyloma acuminatum. Diseases Colon Rectum 1980;23:550-1.

53. Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: A review of intralesional applications. Dermatol Surg 2008;34:1299-313.

54. Ofalsf O, Ofalsf E. Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol 2010;24:1166-70.

55. Singh S, Chouhan K, Gupta S. Intralesional immunotherapy with killed mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts. Indian J Dermatol Venereol Leprol 2014;80:509-14.

56. Saitta P, Krishnamurthy K, Brown LH. Bleomycin in dermatology: A review of intralesional applications. Dermatol Surg 2008;34:1299-313.

57. Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O’Bryan K, et al. Phase 1 clinical trial of intralesional injection of candida antigen for the treatment of warts. Arch Dermatol 2010;146:1431-3.

58. Eassa BI, Abou-Bakr AA, El-Khalawany MA. Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Ther 2011;24:137-43.

59. Wang BY, Johnson DB. Advances in the development of intradermal therapies for melanoma. Melanoma Manag 2016;3:259-66.

60. Vegglaam V, Perumalla N. Intralesional tranexamic acid: Safe and effective way of treatment for melasma. Clin Cosmet Investig Dermatol 2014;7:81-3.

61. Pazyar N, Yaghboobi R, Zeynalie M, Mala S. Comparison of the efficacy of intralesional injected tranexamic acid vs hydroquinone cream in the treatment of melasma. Clin Cosmet Investig Dermatol 2019;12:115-22.

62. Mahajan BB, Kaur S. Interferons. Indian J Dermatol Venereol Leprol 2015;81:51-5.

63. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990;23:694-700.

64. Tourani JM, Leaue JB, Lessana-Leibowitch M, Andrieu JM. Complete remission following recombinant interferon alpha-2a in a patient with diffuse large B cell cutaneous lymphoma. Nuov Rev Fr Haematol 1989;31:315-6.

65. Kätting B, Bonnmann G, Metze D, Luger TA, Cerroni L, Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997;36:311-4.

66. Wollina U. Complete response of a primary cutaneous T-cell-rich B-cell lymphoma treated with interferon alfa2a. J Cancer Res Clin Oncol 1998;124:127-9.

67. Wollina U, Hahnfeld S, Kosmehl H. Primary cutaneous marginal center lymphoma - complete remission induced by interferon alfa2a. J Cancer Res Clin Oncol 1999;125:305-8.

68. Cozio A, Kempf W, Schmid-Meyer R, Gilliet M, Michaeils S, Schäfer L, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma 2006;47:865-9.

69. Oh CK, Son HS, Lee JB, Jang HS, Kwon KS. Intralesional interferon alfa-2b treatment of keratoacanthomas. J Am Acad Dermatol 2008;51:S177-80.

70. Lacy GL 2nd, Adams DM, Hellstrom WJ. Intralesional interferon-alpha2b for the treatment of Peyrin’s disease. Int J Impot Res 2002;14:336-9.

71. Welander CE, Homesley HD, Smiles KA, Peets EA. Intralesional interferon alfa-2b for the treatment of genital warts. Am J Obstet Gynecol 1990;162:348-54.

72. Wolff JM, Zitelli JA, Rabin BS, Smiles KA, Abell E. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol 1985;13:604-12.

73. Intron a-FDA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103132s5190lbl.pdf. [Last accessed 2020 March 12].

74. Reddy GS, Reddy GV, Reddy KS, Priyadarshini BS, Sree PK. Intralesional sclerotherapy—A novel approach for the treatment of intraoral haemangiomas. J Clin Diagn Res 2016;10:ZD13-4.

75. Kaliyadan F, Sundeep V, Hiran KR, Fouzia Z. Late onset eccrine angiomatous hamartoma treated with intralesional sclarosan: A case report and brief review of literature. Indian J Dermatol 2007;52:99-101.

76. Sitra G, Kayalvizhi EB, Sivasankari T, Vishwanath R. A new venture in sclerotherapy in an oral vascular lesion. J Basic Clin Pharm 2014;6:40-3.

77. Shah JS, Ranchani AF. Sclerotherapy in pyogenic granuloma and mucocele. J Indian Acad Oral Med Radiol 2018;30:230-4.

78. Mahajan JK, Bharathi V, Chowdhary SK, Samujh R, Menon P, Rao KLN. Bleomycin as intralesional sclerosant for cystic hygromas. J Indian Assoc Pediatr Surg 2004;9:3-7.

79. Santhi Varndhani G, Rehman Mohd A, Nishat B. Intralesional sclerostan injection for wrist ganglia—a case series. Glob J Res Anal 2018;7:33-5.

80. Lee YJ, Yoo CS, Kim CW, Kim SS. Successful treatment of a pseudocyst of the auricle using intralesional sodium tetradecyl sulfate injection. Dermatol Surg 2013;39:1938-40.

81. Mustaq S, Dogra D, Dogra N. Clinical response with intralesional amphotericin B in the treatment of old world cutaneous leishmaniasis: A preliminary report. Dermatol Ther 2016;29:398-405.

82. Nikandish M, Goyonlo VM, Taheri AR, Khiar B. Ocular leishmaniasis treated by intralesional amphotericin B. J Infect 2013;59:237-8.

83. Eassa BI, Abou-Bakr AA, El-Khalawany MA. Intradermal injection of PPD as a novel approach of immunotherapy in anogenital warts in pregnant women. Dermatol Ther 2011;24:137-43.

84. Wang DY, Johnson DB. Advances in the development of intradermal therapies for melasma. Melanoma Manag 2016;3:259-66.

85. Vegglaam V, Perumalla N. Intralesional tranexamic acid: Safe and effective way of treatment for melasma. India J Drugs Dermatol Venereol Leprol 2017;3:81-3.

86. Pazyar N, Yaghboobi R, Zeynalie M, Mala S. Comparison of the efficacy of intralesional injected tranexamic acid vs hydroquinone cream in the treatment of melasma. Clin Cosmet Investig Dermatol 2019;12:115-22.

87. Mahajan BB, Kaur S. Interferons. Indian J Dermatol Venereol Leprol 2015;81:51-5.

88. Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990;23:694-700.
87. Johnson A, Jennings T. Intralesional methotrexate for treatment of recurrent squamous cell carcinoma on the distal lower extremity. J Am Acad Dermatol 2017;76:AB417.

88. Brambilla L, Bellinvia M, Tournalaki A, Scoppio B, Gaiani F, Boneschi V. Intralesional vincristine as first-line therapy for nodular lesions in classic kaposi sarcoma: A prospective study in 151 patients. Br J Dermatol 2010;162:854-9.

89. Epstein JB. Treatment of oral kaposi sarcoma with intralesional vinblastine. Cancer 1993;71:1722-5.

90. Levine LA, Estrada CR. Intralesional verapamil for the treatment of pyorrheonic disease: A review. Int J Implant Res 2002;14:324-8.

91. Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 2008;74:343-8.

92. Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns 2014;40:583-8.

93. Suárez Valladares MJ, Eiris Salvado N, Rodríguez Prieto MA. Treatment of hidradenitis suppurativa with intralesional photodynamic therapy with 5-aminolevulinic acid and 630 nm laser beam. J Dermatol Sci 2017;85:241-6.

94. Suárez Valladares MJ, Rodríguez Prieto MA. Treatment of myxoid cysts with intralesional photodynamic therapy: A case series. J Am Acad Dermatol 2017;76:359-60.

95. Lee DJ, Kim EH, Jang YH, Kim YC. Photodynamic therapy with 5-aminolevulinic acid intralesional injection for pyogenic granuloma. Arch Dermatol 2012;148:126-8.

96. Cappugi P, Mavilia L, Campolmi P, Reali EF, Mori M, Rossi R. New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-aminolevulinic acid. J Chemother 2004;16:491-3.

97. Ryou JH, Lee SJ, Park YM, Kim HO, Kim HS. Acne-photodynamic therapy with intralesional injection of 5-aminolevulinic acid. Photodermatol Photoimmunol Photomed 2009;25:57-8.

98. Vinay K, Kanwar AJ, Mittal A, Dogra S, Minz RW, Hashimoto T. Intralesional rituximab in the treatment of refractory oral pemphigus. J Dermatol Ther (Heidelb) 2016;6:169-83.

99. Mohamed EE, Tawfik KM, Mahmoud AM. The clinical effectiveness of intralesional injection of 2% zinc sulfate solution in the treatment of common warts. Scientifica (Cairo) 2016;2016:1082979.

100. Upadhyaya VD, Bhattacharya K, Sahu PK, Naveed A, Sinha S. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004;209:46-9.

101. El Taweel AA, Salem R, Allam A. Intralesional 2% zinc sulfate solution for plane warts: A case report. Dermatol Ther 2019;32:e12761.

102. Iraji F, Vali A, Asilian A, Shahtalebi MA, Momeni AZ. Comparison of intralesionally injected zinc sulphate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004;209:46-9.

103. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimonials intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One 2017;12:e0184777.

104. Alwan AA, Alnassar M, Alshayeb M, Alkayal A, Alabrash A, Al-Sayed A. Effectiveness of intralesional vitamin D3 injection in the treatment of common warts: Single-blinded placebo-controlled study. Dermatol Ther 2019;32:e12882.

105. Shah PH, Venkatesh R, More CB, Vassandacoumara V. Comparison of therapeutic efficacy of placental extract with dexamethasone and hyaluronic acid with dexamethasone for oral submucous fibrosis—A retrospective analysis. J Clin Diagn Res 2016;10:ZC63-6.

106. Raghukumar S, Ravikumar BC, Vinay KN, Suresh MR, Aggarwal A, Yashovardhana DP. Intralesional vitamin D3 injection in the treatment of recalcitrant warts: A novel proposition. J Cutan Med Surg 2017;21:320-4.

107. Kavya M, Shashikumar BM, Harish MR, Shweta BP. Safety and efficacy of intralesional vitamin D3 in cutaneous warts: An open uncontrolled trial. J Cutan Aesthet Surg 2017;10:90-4.

108. Kareem IMA, Ibrahim IM, Mohammed SFF, Ahmed AA. Effectiveness of intralesional vitamin D3 injection in the treatment of common warts: Single-blinded placebo-controlled study. Dermatol Ther 2019;32:e12882.

109. Chia-Han Yeh M, Tsai TY, Huang YC. Intralesional vitamin D3 injection in the treatment of warts: A systematic review and meta-analysis. J Am Acad Dermatol 2020;82:1013-5.

110. El Taweel AA, Salem R, Allam A. Intralesional 2% zinc sulfate solution for plane warts: A case report. Dermatol Ther 2019;32:e12761.

111. Mohamed EE, Tawfik KM, Mahmoud AM. The clinical effectiveness of intralesional injection of 2% zinc sulfate solution in the treatment of common warts. Scientifica (Cairo) 2016;2016:1082979.

112. Iraji F, Vali A, Asilian A, Shahtalebi MA, Momeni AZ. Comparison of intralesionally injected zinc sulphate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004;209:46-9.

113. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimonials intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One 2017;12:e0184777.

114. Callen JP. Intralesional corticosteroids. J Am Acad Dermatol 1981;4:149-51.

115. Shah VV, Al-Dahash AH, Al-Saif F, Alsaif S, Alothman R, Al-Shalabi S, Al-Saadi S. Efficacy of intralesional sodium thiosulfate. Medical Dermatology. Available from: http://www.aad.org/dw-insights-and-inquiries/medical-dermatology/software-thow-of-calcinosis-cuts-the-promise-of-intralesional-sodium-thiosulfate. [Last accessed 2020 Jan 2].

116. Upadhyaya VD, Bhattacharya K, Sahu PK, Naveed A, Sinha S. Comparison of intralesionally injected zinc sulphate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004;209:46-9.

117. Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single session of intralesional bleomycin injection in the treatment of warts: A novel retrospective analysis. J Drugs Dermatol 2016;15:648-51.

118. Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC. Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature. J Am Acad Dermatol 2007;56:989-93.

119. Maillet-Lebel N, Thibeault MM. Intralesional rituximab for cutaneous manifestations of systemic B-cell lymphoma. JAAD Case Rep 2016;2:334-6.
**Supplementary Material**

**Supp I: Level of evidence (LoE)**

- **Level Ia:** Systemic review of randomized control trials
- **Level Ib:** Individual randomized control trials
- **Level IIa:** Systemic review of the cohort study
- **Level IIb:** Individual cohort study
- **Level IIIa:** Systemic review of a case-control study
- **Level IIIb:** Individual case-control study
- **Level IV:** Case series
- **Level V:** Expert opinion without explicit critical appraisal and/or reports of expert committees. Based on physiology and bench research, text book, literature review.

**Supp II: Specific side effect for various IL drug therapy**

| IL drugs                          | Associated side effects                                                                                                                                                                                                 |
|-----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Corticosteroid injections         | Atrophy, pain, hemorrhage, ulceration, hyper- or hypopigmentation, perilesional linear atrophy and hypo pigmentation, calcification, secondary infection, granuloma formation, allergic reaction, hypothalamus–pituitary–adrenal axis suppression, endocrine changes like hirsutism, striae, moon faces, and buffalo hump, growth retardation in young children, syncope, blindness |
| 5-Fluorouracil                    | Pain, necrosis, hyperpigmentation, pruritus, partial wound dehiscence, local infection, ulceration, and atrophic scarring                                                                                                   |
| Botulinum toxin and fillers       | Edema, pain, erythema, temporary hypesthesia and over- or under-correction                                                                                                                                                |
| Platelet-rich plasma (PRP)        | Relatively safe with no risk of hypersensitivity                                                                                                                                                                         |
| Mesotherapy                       | Pain, edema, erythema, local infection or abscess, lichenoid eruptions, hyperpigmentation and hypersensitivity reactions                                                                                               |
| Cryotherapy                       | Pain, erythema, hypo- or hyperpigmentation at the site of injections                                                                                                                                                   |
| Interferons                       | Flu-like symptoms, pancytopenia, hypocalcemia, hyperlipidemia, depression, cardiac arrhythmias, gastrointestinal upset, renal toxicity, alopecia, xerosis, injection site reactions, and menstrual irregularities |
| Bleomycin                         | Redness, swelling, pain and burning subsides. Rare side effects are Raynaud's phenomenon, narrowing of fingertips, restricted nail growth, scarring, lymphangitis, paresthesias, and hematoma formation |
| Immunotherapy                     | Pain, pruritus, chills, transient erythema, edema, induration at the injection site, burning sensation, pruritus, myalgia, infection, watering, ulcers, scarring, and hypo- or hyper pigmentation, autism in case of vaccines controversial granulomatous hepatitis and arthralgia |
| Sclerosants                       | Nicolau syndrome, which manifests with tissue necrosis, in a single case of pyogenic granuloma. Other complications include pain, ecchymosis, hyperpigmentation, necrosis, ulceration, and thrombophlebitis |
| Amphotericin-B                    | Local pain, fibrosis, local allergic reaction, transient erythema and pain at the injection site, mild burning sensation, and transient chemosis                                                                 |
| Methotrexate                      | Ulceration, necrosis, and pancytopenia                                                                                                                                                                                   |
| Vincrisine and Vinblastine        | Pain, erythema, and pruritus                                                                                                                                                                                             |
| Verapamil                         | No major side effects have been noted except for rare injection site reactions.                                                                                                                                           |
| Photodynamic therapy             | Injection site reactions                                                                                                                                                                                                  |
| Rituximab                         | Injection site reactions                                                                                                                                                                                                  |
| Cyclosporine                      | Injection site reactions                                                                                                                                                                                                  |
| Mistletoe extract                 | Injection site reactions, occasionally, mild uterine contractions may occur starting about 6 h after application and lasting about 1 h and mild headache                                                                      |
| Placental extract                 | Mild local pain following the injections                                                                                                                                                                                   |
| Vitamin D3                        | Transient mild to moderate pain, itching, edema at the site of injection, mild erythema. Rare side effect like dyspigmentation. No signs of hypervitaminosis D or systemic side effects |
| Sodium thiosulfate                | Transient local pain during injection                                                                                                                                                                                     |
| 2% zinc sulfate                   | Early complications (pain, tenderness, or swelling) and late complications (postinflammatory hyperpigmentation, scarring, ulceration)                                                                                           |